Peritonitis, gastric and hepatic disorders and gastrointestinal surgery: Patients with a recent history of peritonitis (within the last 3 months), significant gastric or hepatic disorders and patients with major gastrointestinal surgery have not been included in clinical studies with Velphoro. Velphoro should only be used in these patients following careful assessment of benefit/risk.
Information about sucrose and starches (carbohydrates): Velphoro contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
It may be harmful to the teeth.
Velphoro contains potato starch and pregelatinised maize starch. Patients with diabetes should take notice that one tablet of Velphoro is equivalent to approximately 1.4 g of carbohydrates (equivalent to 0.116 bread units).
Discoloured stool: Velphoro can cause discoloured (black) stool. Discoloured (black) stool may visually mask gastrointestinal bleeding (see Interactions).
Effects on ability to drive and use machines: Velphoro has no or negligible influence on the ability to drive and use machines.